Markets & Investing
Numinus Sees Revenue Dip, Improved Margins in Q1
The firm has been adopting an asset-light clinical model.
The post Numinus Sees Revenue Dip, Improved Margins in Q1 appeared first on Green Market Rep…
Psychedelic-assisted therapy provider Numinus Wellness Inc. (OTCQX: NUMIF) released its financial results for the first quarter of fiscal 2024, which showed a nuanced performance, with a modest slump in revenue but increased operational efficiency.
The company’s revenue for the quarter ending Nov. 30, 2023, was $5.9 million, a 3% decline from the previous quarter. Revenue was up 4.9% versus the same quarter the previous year.
That fluctuation is partly due to a shift towards more profitable operations, according to the company, leading to a lower number of appointments at its wellness clinics. Numinus reported a $4.4 million net loss versus a $6.3 million net loss in the previous year’s first period, according to filings.
According to CEO Payton Nyquvest, Numinus has focused on enhancing its practitioner training program and clinical infrastructure to meet growing demand for novel mental health treatments.
“This infrastructure is built on Numinus’ synergistic combination of a clinic network that delivers high-quality patient care, clinical research support that works with leading psychedelic drug developers, and training programs that ensure effective and safe support is available for patients into the future,” Nyquvest said.
A key aspect of the firm’s strategy has been cost containment. The company reported a monthly cash burn rate of less than $1 million for the period, a continuation of efforts that began in October 2023. That has resulted in a 19.9% decline in operating expenses versus the previous quarter and a 30.6% reduction versus the first quarter of last year.
Consequently, the gross margin improved to 36.1% from 29.5% in the previous quarter.
The performance of Numinus’ wellness clinics also alluded to that rightsizing, with revenue of $4.9 million for the quarter, a slight year-over-year slump. The company’s emphasis on higher-margin services led to a reduction in the number of clinical appointments.
Regarding clinical research, the company reported mixed results. Revenue from clinical and contract research fell by 12.9% from the previous quarter, but it rose 49.5% versus the same quarter last year. Numinus said it continues to participate in clinical trials and has introduced comprehensive psychedelic programs at its facilities.
As of the end of the quarter, Numinus reported a total cash balance of $4.7 million and working capital of $4.6 million. The company’s board of directors kickstarted a strategic review process to explore options for enhancing shareholder value, with no specific timeline set for its completion.
The post Numinus Sees Revenue Dip, Improved Margins in Q1 appeared first on Green Market Report.
psychedelic capital research-
Psilocybin1 week ago
California advances bill for psychedelics centers
-
Psilocybin5 days ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Psychedelics1 week ago
Psychedelics Can Offer More Than Therapy On Its Own
-
Psychedelics4 days ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics5 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics5 days ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psychedelics5 days ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psychedelics5 days ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment